Newcastle Disease Virus at the Forefront of Cancer Immunotherapy

摘要: Preclinical and clinical studies dating back to the 1950s have demonstrated that Newcastle disease virus (NDV) has oncolytic properties can potently stimulate antitumor immune responses. NDV selectively infects, replicates within, lyses cancer cells by exploiting defective antiviral defenses in cells. Inflammation within tumor microenvironment response leads recruitment of innate adaptive effector cells, presentation antigens, induction checkpoints. In animal models, intratumoral injection results T cell infiltration both local distant non-injected tumors, demonstrating potential activate systemic immunity. The combination with checkpoint blockade regression injected an effect further potentiated introduction immunomodulatory transgenes into viral genome. Clinical trials naturally occurring administered intravenously durable responses across numerous types. Based on these studies, exploration is warranted, using recombinant been initiated.